Press Releases

ThermoGenesis Holdings Begins a Year of Celebration of its 35th Anniversary in the Cell Banking and Cell Therapy Industry

Future corporate strategy targets large-scale cellular manufacturing needs for upcoming cell and gene therapies RANCHO CORDOVA, Calif., Feb. 17, 2021 — ThermoGenesis Holdings, Inc. (“ThermoGenesis” or the “Company”) (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, announced today that the Company will kick off a … Continued

ThermoGenesis Holdings Launches a GMP Compliant Automated Cell Washing and Reformulation System — PXP™-LAVARE — for CAR-T Manufacturing

RANCHO CORDOVA, Calif., Feb. 3, 2021 — ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced that it has completed the development process, submitted a Letter to File and updated the device listing with the U.S. Food and Drug Administration (FDA) … Continued

ThermoGenesis Holdings to Participate at the H.C. Wainwright BIOCONNECT 2021 Conference

RANCHO CORDOVA, Calif., Jan. 7, 2021 — ThermoGenesis Holdings, Inc. (Nasdaq: THMO) a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced that Jeff Cauble, Chief Financial Officer, will present a company overview at the H.C. Wainwright BIOCONNECT 2021 Conference. The presentation will be available beginning January … Continued

ThermoGenesis Holdings Announces Financial Results for the Third Quarter Ended September 30, 2020 and Provides Corporate Update

Conference Call to be Held Today at 1:30 p.m. PT/4:30 p.m. ET RANCHO CORDOVA, Calif., Nov 12, 2020 — ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced financial and operating results for the third quarter ended September 30, 2020 … Continued

ThermoGenesis Holdings to Announce Financial Results for the Third Quarter Ended September 30, 2020 and Provide a Corporate Strategic Update

Conference Call to be Held on November 12, 2020 RANCHO CORDOVA, Calif., November 5, 2020 — ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced that the Company will release its financial results for the third quarter ended September 30, 2020 … Continued

Facilitating the ‘Vaccine Era’ of COVID-19 Response: ThermoGenesis to Receive U.S. Patent for Breakthrough Serological Test Reader Technology

RANCHO CORDOVA, Calif., October 20, 2020 — ThermoGenesis Holdings, Inc. (Nasdaq: THMO) today announced that it has received notification from the United States Patent and Trademark Office (USPTO) of its intent to issue U.S. Patent No. 10,823,746 on November 3, for the Company’s new breakthrough lateral flow immunoassay test reader technology, the ThermoGenesis Reader. The … Continued

ThermoGenesis Unveils Comprehensive Suite of Products and Services to Fight the Global COVID-19 Pandemic

RANCHO CORDOVA, Calif., Sept 2, 2020 — ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, along with its joint venture, ImmuneCyte, Inc. today announced plans to roll out a comprehensive diagnostic and therapeutic product line to fight the global COVID-19 pandemic. The multi-pronged … Continued

ThermoGenesis Holdings to Participate in Investor Conferences in September

RANCHO CORDOVA, Calif., Aug. 31, 2020 — ThermoGenesis Holdings, Inc. (Nasdaq: THMO) a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced management’s participation in the following investor conferences in September.   September 1-4: LD Micro 500. Chris Xu, Ph.D., Chief Executive Officer of ThermoGenesis, will present … Continued

ThermoGenesis Enters Into Supply Agreement with New EUA Approved COVID-19 Antibody Test Manufacturer; Marketing to Begin on August 17, 2020

RANCHO CORDOVA, Calif., August 13, 2020 — ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, announced that on August 12, the Company entered into a supply agreement with BioHit Healthcare (Hefei) Co., Ltd. to market, under the ThermoGenesis brand, its SARS-CoV-2 IgM/IgG Antibody … Continued

© 2024 ThermoGenesis Holdings, Inc.
How may we help?